Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Moderna"


25 mentions found


TOKYO/NEW YORK (Reuters) - Asian shares rose on Wednesday after a strong lead from Wall Street fuelled by hopes for additional U.S. economic stimulus and a coronavirus vaccine, but trade was choppy as some investors booked profits. REUTERS/Issei KatoTop U.S. Senate Republican Mitch McConnell said on Tuesday that Congress should include new coronavirus stimulus in a $1.4 trillion spending bill aimed at heading off a government shutdown in the midst of the pandemic. MSCI’s broadest index of Asia-Pacific shares outside Japan rose 0.27%, but was still trading below last week’s all-time high. U.S. stock futures declined 0.23% following a record closing high for Wall Street shares. Pfizer Inc and Germany’s BioNTech SE sought emergency approval of their vaccine candidate from the European regulator on Tuesday.
Persons: Issei Kato Top, Senate Republican Mitch McConnell, Joe Biden, DAX, “ We’ve, , Michael McCarthy, , BioNTech, Softbank, ” Andrew Brenner, SoftBank Organizations: TOKYO, Wall, REUTERS, Issei Kato Top U.S, Senate Republican, New York Times, Top, Softbank Group, Bloomberg News, Amazon.com Inc, Facebook Inc, South, Wall Street, Benchmark U.S, Treasury, CMC Markets, Pfizer Inc, Moderna Inc, Pfizer, Union, NatAlliance Securities, OPEC, Brent Locations: Tokyo, Japan, Top U.S, Asia, Pacific, China, Europe, U.S, ” Andrew Brenner , New York
Asian stocks rise after vaccine optimism drives Wall Street to record highs
  + stars: | 2020-12-02 | by ( Jessica Dinapoli | ) www.reuters.com sentiment -0.94   time to read: +2 min
NEW YORK (Reuters) - Asian markets were set to climb on Wednesday after Wall Street indexes closed at record highs as investors grow increasingly hopeful about a vaccine to combat rising COVID-19 cases and an economic recovery. FILE PHOTO: People wearing protective face masks, following an outbreak of the coronavirus, are reflected on a screen showing Nikkei index, outside a brokerage in Tokyo, Japan February 28, 2020. The futures contract for the Nikkei 225 index rose 0.15% on Wednesday while Hong Kong’s Hang Seng index futures rose 0.31%. Pfizer Inc and Germany’s BioNTech SE sought emergency approval of their vaccine candidate from the European regulator on Tuesday. Competitor Moderna Inc also applied for emergency approval from the European regulator on Tuesday.
Persons: “ We’ve, , Michael McCarthy, , Australia’s, BioNTech, Senate Republican Mitch McConnell, Brent Organizations: YORK, REUTERS, CMC Markets, Nikkei, Pfizer Inc, Moderna Inc, Pfizer, Union, U.S, Senate Republican, Treasury Locations: Tokyo, Japan, U.S
Full coverage of the coronavirus outbreakThe panel of outside scientific experts makes recommendations to the CDC, which almost always accepts them. The two groups in Phase 1a together represent around 24 million Americans - 21 million health care workers and 3 million residents of long-term care facilities. Staff working at long-term care facilities are considered among the health care workers. For example, health care workers with direct patient contact would be among the first to be offered the vaccine, as well as individuals working in long-term care facilities. “I do not feel like our safety network for long-term care facilities is strong enough yet,” Talbot said.
Persons: José Romero, ACIP, Beth Bell, We're, it's, , Nancy Messioner, Helen Talbot, Talbot, ” Talbot, , Dr, William Schaffner, “ Long, Schaffner Organizations: for Disease Control, CDC, Food and Drug Administration, Pfizer, Moderna, Staff, University of Washington, National Center, Safety, FDA, Vanderbilt University, Vanderbilt University Medical Center, NBC, Twitter, Facebook Locations: U.S, Nashville , Tennessee
FILE PHOTO: The word "COVID-19" is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. There are an estimated 21 million healthcare workers and an additional 3 million nursing home residents in the United States. Although panel members universally endorsed the recommendation to include frontline healthcare workers in the initial allocation, several members of the panel voiced concerns about the inclusion of long-term care residents. Ultimately, most members endorsed the early use of the vaccines in long-term care residents, who make up 6% of COVID-19 cases and nearly 40% of related deaths, according to the CDC. For long-term care residents, the consent forms will also explain that the vaccines have not been tested in that population, and families may be included in conversations about potential risks as needed.
Persons: Dado Ruvic, Nancy Messonnier Organizations: CHICAGO, U.S . Centers for Disease Control, Prevention, REUTERS, Moderna Inc, Pfizer Inc, BioNTech, CDC’s National Center, CDC, Moderna, Pfizer, U.S . Food, Drug Locations: United States, U.S
REUTERS/Kevin Lamarque(Reuters) - Healthcare workers and others recommended for the first COVID-19 inoculations could start getting shots within 24 hours after the vaccine receives regulatory authorization, the chief adviser for the U.S. government’s Operation Warp Speed program said on Tuesday. “Within 24 hours, maybe at most 36 to 48 hours, from the approval, the vaccine can be in people’s arms,” Slaoui said at an event conducted by The Washington Post. Slaoui said the federal government will ship doses to the locations identified in state plans. The United States should have 60 million to 70 million doses a month by January, between both the Pfizer and Moderna Inc vaccines, Slaoui said. Moderna’s vaccine, which was about equally effective, will be reviewed by the expert panel a week after Pfizer’s.
Persons: Moncef Slaoui, Donald Trump, Kevin Lamarque, Moncef, ” Slaoui, Slaoui Organizations: GlaxoSmithKline, White, REUTERS, Healthcare, U.S, U.S ., , The Washington Post, Pfizer Inc, U.S . Food, Drug Administration, Pfizer, BioNTech, FDA, Moderna Inc Locations: Washington , U.S, U.S, COVID, United States
“Within 24 hours, maybe at most 36 to 48 hours, from the approval, the vaccine can be in people’s arms,” Slaoui said at an event conducted by The Washington Post. Pfizer applied for the EUA on Nov. 20 after publishing data that showed the vaccine developed with German partner BioNTech SE was 95% effective in preventing COVID-19. The United States should have 60 million to 70 million doses a month by January, between both the Pfizer and Moderna Inc vaccines, Slaoui said. J&J has said that it is on track to release an interim analysis of its large vaccine trial late this year or early next year. AstraZeneca said that it will likely run an additional global trial using that dosing regimen to confirm those results.
Persons: Moncef Slaoui, Donald Trump, Kevin Lamarque Moncef, ” Slaoui, Slaoui Organizations: Reuters, Healthcare, U.S, GlaxoSmithKline, White, REUTERS, U.S ., , The Washington Post, Pfizer Inc, U.S . Food, Drug Administration, Pfizer, BioNTech, FDA, Moderna Inc, Johnson, AstraZeneca, Speedy, Oxford University Locations: Washington , U.S, U.S, COVID, United States
(Reuters) - Wall Street’s main indexes were set to open higher on Tuesday as better-than-expected factory data from China and hopes that a COVID-19 vaccine will be rolled out before the end of the year bolstered bets of a speedy economic recovery. FILE PHOTO: A Wall St. sign is seen near the New York Stock Exchange (NYSE) in the financial district in New York, U.S., November 24, 2020. REUTERS/Brendan McDermid/File PhotoInvestors are closely following updates on a handful of leading vaccine candidates as well as the start of global shipments as drugmakers submit paperwork for regulatory approvals. ET, Dow E-minis were up 299 points, or 1.01% and S&P 500 E-minis were up 0.93%. Tesla Inc rose about 4.5% after S&P Dow Jones Indices said it would add one of Wall Street’s most valuable companies to the S&P 500 index all at once on Dec. 21.
Persons: Brendan McDermid, , Steven Blitz, Dow, Steven Mnuchin, Jerome Powell, Powell Organizations: Reuters, New York Stock Exchange, REUTERS, Pfizer Inc, Moderna, TS Lombard, Investors, Carnival Corp, Royal Caribbean Cruises Ltd, Delta Air Lines Inc, United Airlines Holdings, Big, Dow E, Nasdaq, Federal, Communications, Tesla, Dow Jones Indices Locations: China, New York, U.S, EU, United States, California, Big U.S
(Reuters) - The S&P 500 and the Nasdaq hit record highs on Tuesday as hopes that a COVID-19 vaccine will be available soon and better-than-expected factory data from China bolstered bets of a speedy economic recovery. “The optimism continues to build for a vaccine to come out and be very successful... ET, the Dow Jones Industrial Average rose 409.86 points or 1.38% to 30,048.50, the S&P 500 gained 49.33 points, or 1.36% to 3,670.96 and the Nasdaq Composite gained 136.25 points or 1.12% to 12,334.61. Tesla Inc rose about 3% after S&P Dow Jones Indices said it would add one of Wall Street’s most valuable companies to the S&P 500 index all at once on Dec. 21. The S&P 500 posted 31 new 52-week highs and no new low, while the Nasdaq recorded 212 new highs and seven new lows.
Persons: , Larry Adam, Raymond James, Dow, China’s, Steven Mnuchin, Jerome Powell Organizations: Reuters, Nasdaq, Pfizer Inc, Moderna, Investors, Dow Jones, Federal, Communications, Tesla, Dow Jones Indices, Micron Technology, NYSE Locations: China, COVID, California
S&P 500, Nasdaq hit records on vaccine optimism
  + stars: | 2020-12-01 | by ( Noel Randewich | ) www.reuters.com + 0.00   time to read: +3 min
(Reuters) - The S&P 500 and Nasdaq Composite indexes jumped to record highs on Tuesday, with investors betting a COVID-19 vaccine will be available soon, and more confident about a speedy economic recovery following upbeat Chinese factory data. All 11 S&P 500 sector indexes rose, with communication services jumping 2.4% and leading gains. The Dow Jones Industrial Average was up 0.92% at 29,910.46 points, while the S&P 500 gained 1.42% at 3,673.05. Tesla Inc rose 2.4% after S&P Dow Jones Indices said it would add one of Wall Street’s most valuable companies to the S&P 500 index all at once on Dec. 21, rather than in two chunks. The S&P 500 posted 48 new 52-week highs and no new lows; the Nasdaq Composite recorded 175 new highs and seven new lows.
Persons: Dado Ruvic, , Bill Northey, Steve Mnuchin, Jerome Powell, Nancy Pelosi, Dow Organizations: Reuters, Nasdaq, REUTERS, Pfizer Inc, Moderna Inc, U.S, Bank Wealth Management, Investors, Treasury, Federal, Senate Banking Committee, Dow Jones, Communications, Tesla, Dow Jones Indices, Micron Technology Inc, NYSE Locations: U.S, Minneapolis, United States
S&P 500, Nasdaq end at record highs on vaccine optimism
  + stars: | 2020-12-01 | by ( Noel Randewich | ) www.reuters.com + 0.00   time to read: +2 min
(Reuters) - The S&P 500 and Nasdaq Composite indexes closed at record highs on Tuesday, with investors betting a COVID-19 vaccine will be available soon, and more confident about a speedy economic recovery following upbeat Chinese factory data. Several other countries also reported sharp upticks in factory activity. All 11 S&P 500 sector indexes rose, with communication services among the leading gainers. All three main stock indexes gained more than 10% in November. Tesla Inc rose after S&P Dow Jones Indices said it would add one of Wall Street’s most valuable companies to the S&P 500 index in one go on Dec. 21, rather than in two tranches.
Persons: , Bill Northey, Steve Mnuchin, Jerome Powell, Dow Organizations: Reuters, Nasdaq, Pfizer Inc, Moderna Inc, U.S, Bank Wealth Management, Treasury, Federal, Senate Banking Committee, Dow Jones, Communications, Tesla, Dow Jones Indices, Micron Technology Inc Locations: Minneapolis, U.S
WASHINGTON (Reuters) - The United States entered the final month of the year hoping that promising vaccine candidates will soon be approved to halt the rapidly spreading novel coronavirus after 4.2 million new cases were reported in November. FILE PHOTO: A health worker provides a COVID-19 test at a drive-through testing site, as the coronavirus disease (COVID-19) continues to spread, in Staten Island, New York, U.S. November 25, 2020. “One hundred percent of the Americans that want the vaccine will have the vaccine by (June). We will have over 300 million doses available to the American public well before then,” Paul Ostrowski, the vaccine program’s director of supply, production and distribution, told MSNBC television on Monday. “If these trends continue, we’re going to have to take much more dramatic, arguably drastic, action.”
Persons: Brendan McDermid, Donald Trump’s, Johnson, ” Paul Ostrowski, Webster, Trump, Joe Biden, Biden, California’s, Gavin Newsom Organizations: WASHINGTON, United, REUTERS, U.S . Food, Drug Administration, Pfizer Inc, Moderna Inc, AstraZeneca PLC, Johnson, Trump, MSNBC, Reuters, Merriam Locations: United States, Staten Island , New York, U.S,
WASHINGTON (Reuters) - U.S. officials on Monday unveiled details for the swift distribution of COVID-19 vaccines to millions of Americans after the United States broke records for new coronavirus infections and hospitalizations. FILE PHOTO: A health worker provides a COVID-19 test at a drive-through testing site, as the coronavirus disease (COVID-19) continues to spread, in Staten Island, New York, U.S. November 25, 2020. The U.S. Transportation Department said on Tuesday it has made preparations to enable the “immediate mass shipment” of COVID-19 vaccines and completed all necessary regulatory measures. A CDC advisory panel is due to vote on Tuesday afternoon on recommendations for which Americans should get the vaccine first. A record of nearly 96,000 COVID-19 patients were in hospitals on Tuesday, according to a Reuters tally.
Persons: Brendan McDermid, Donald Trump’s, ” Moncef, Slaoui, Johnson, , Dave Chokshi, ” Chokshi, Bill de Blasio, ” de Blasio Organizations: WASHINGTON, United States, REUTERS, GlaxoSmithKline, The Washington, Pfizer Inc, Moderna Inc, Drug Administration, Pfizer, Moderna, AstraZeneca Plc, Johnson, U.S . Transportation Department, U.S . Centers for Disease Control, Prevention, CDC, Reuters, University of Washington’s Institute for Health Metrics, American Health Care Association, National Center for Locations: United, Staten Island , New York, U.S, United States, ebbing, New York City, New
WASHINGTON (Reuters) - U.S. officials on Tuesday unveiled plans to begin vaccinating millions of Americans against COVID-19 as early as mid-December, as coronavirus infections and hospitalizations in the United States soared once more to unprecedented heights. Some 60 million to 70 million doses of COVID-19 vaccine could be available per month beginning in January, after the expected regulatory approval of products from Pfizer Inc and Moderna Inc, Slaoui said. The CDC will take the recommendation into account and provide guidance to the states to assist governors in their decisions about vaccine distribution priorities. Slideshow ( 3 images )New York Governor Andrew Cuomo on Tuesday complained about the lack of federal funding for vaccine distribution. A record nearly 96,000 COVID-19 patients were reported in U.S. hospitals on Tuesday, according to a Reuters tally.
Persons: Donald Trump’s, ” Moncef, Slaoui, Alex Azar, Peter Marks, Stephen Hahn, Trump, Hahn, Andrew Cuomo, ” Cuomo, , Dave Chokshi, ” Chokshi, Organizations: WASHINGTON, COVID, GlaxoSmithKline, The Washington Post, Pfizer Inc, Moderna Inc, Drug Administration, Pfizer, . Health, Human Services, FDA’s, Biologics, ABC, U.S . Transportation Department, U.S . Centers for Disease Control, Prevention, CDC, New, . Immigration, Customs Enforcement, Reuters, University of Washington’s Institute for Health Metrics, U.S, American Health Care Association, National Center for, . New York City Health Locations: United, United States, U.S, New York, ebbing, . New York City
WASHINGTON (Reuters) - Top U.S. health officials announced plans on Tuesday to begin vaccinating Americans against the coronavirus as early as mid-December, as nationwide deaths hit the highest number for a single day in six months. Officials in several states said numbers were higher in part due to a backlog from the Thanksgiving holiday. A statement from the public health director for Los Angeles County highlighted the ravages of the surging pandemic. Barbara Ferrer, the public health director, said that while Tuesday was the county’s “worst day thus far” of the pandemic, “...it will likely not remain the worst day of the pandemic in Los Angeles County. Hospitalizations and deaths are expected to spike even higher during the holiday travel season, a trend that officials warn could overwhelm already strained healthcare systems.
Persons: Donald Trump’s, ” Moncef, Barbara Ferrer, Slaoui, Alex Azar, Peter Marks, Stephen Hahn Organizations: WASHINGTON, COVID, , GlaxoSmithKline, U.S ., The Washington Post, Los, , U.S . Centers for Disease Control, CDC, Pfizer Inc, Moderna Inc, Drug Administration, Pfizer, BioNTech, Human Services, FDA’s, Biologics, U.S . Transportation Department, American Health Care Association, National Center for, Reuters, University of Washington’s Institute for Health Metrics Locations: California, U.S, Los Angeles, Los Angeles County, COVID, ebbing
Moderna files for European authorization of COVID-19 vaccine candidate
  + stars: | 2020-12-01 | by ( Reuters Staff | ) www.reuters.com sentiment -1.00   time to read: 1 min
A small shopping basket filled with vials labeled "COVID-19 - Coronavirus Vaccine" and a medical sryinge are placed on a Moderna logo in this illustration taken November 29, 2020. Picture taken November 29, 2020. REUTERS/Dado Ruvic/Ilustration(Reuters) - The European Medicines Agency said on Tuesday it has received an application for marketing authorization for Moderna Inc’s COVID-19 vaccine candidate.
Persons: Dado Ruvic Organizations: REUTERS, European Medicines Agency, Moderna Inc’s
Pfizer-BioNTech apply for EU emergency authorization for COVID-19 vaccine
  + stars: | 2020-12-01 | by ( Reuters Staff | ) www.reuters.com sentiment -1.00   time to read: +1 min
FILE PHOTO: A small shopping basket filled with vials labeled "COVID-19 - Coronavirus Vaccine" is placed on a Pfizer logo in this illustration taken November 29, 2020. REUTERS/Dado Ruvic/IlustrationFRANKFURT (Reuters) - Pfizer Inc and BioNTech have applied to the European drugs regulator for conditional authorization of their COVID-19 vaccine, following similar steps in the United States and Britain, the companies said on Tuesday. The application to the European Medicines Agency (EMA) comes after the companies applied for U.S. approval on Nov. 20, taking them a step closer to launching their vaccine. The European filing completes the so-called rolling review process, which was initiated with the EMA on Oct. 6. The British government said here last week that the U.S.-German partners had reported the data from their clinical trials to the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Persons: Dado Ruvic, Germany’s BioNTech Organizations: Pfizer, REUTERS, Pfizer Inc, European Medicines Agency, Moderna, EMA, UK Medicines, Healthcare, Agency Locations: FRANKFURT, United States, Britain, EU, COVID, U.S
FILE PHOTO: A small shopping basket filled with vials labeled "COVID-19 - Coronavirus Vaccine" is placed on a Pfizer logo in this illustration taken November 29, 2020. REUTERS/Dado Ruvic/IlustrationFRANKFURT (Reuters) - Pfizer Inc and BioNTech’s COVID-19 vaccine could be rolled out in Europe this month, the companies said on Tuesday after they applied for EU emergency approval for the shot. The application to the European Medicines Agency (EMA) comes days after the companies applied for emergency use of their vaccine in the United States. In their pursuit of a European launch, the partners are neck-and-neck with rival Moderna, which said on Monday it would ask the EU regulator to recommend conditional approval for its shot. The European filing completes the so-called rolling review process, which was initiated with the EMA on Oct. 6.
Persons: Dado Ruvic, BioNTech’s, , Germany’s BioNTech, BioNTech Organizations: Pfizer, REUTERS, Pfizer Inc, European Medicines Agency, COVID, CMA, Moderna, EU, United, EMA, Medicines, Healthcare, Agency Locations: FRANKFURT, Europe, United States, European Union, EU, COVID
FRANKFURT (Reuters) - Moderna and Pfizer-BioNTech are in a tight race to launch their COVID-19 vaccines in Europe after both applied for emergency EU approval on Tuesday, though there was uncertainty over whether a rollout could begin this year. FILE PHOTO: A small shopping basket filled with vials labeled "COVID-19 - Coronavirus Vaccine" is placed on a Pfizer logo in this illustration taken November 29, 2020. U.S. drugmaker Pfizer and its German development partner BioNTech said their vaccine could be launched in the European Union as early as this month. “We can start to deliver within a few hours (of an approval),” said Sierk Poetting, head of operations and finance at BioNTech. The EMA said on Tuesday it had started a rolling review of Johnson & Johnson’s vaccine candidate after preliminary results showed it triggered production of antibodies and immune cells against the virus.
Persons: Dado Ruvic, BioNTech, , Sierk Poetting, Jan, Johnson Organizations: Moderna, Pfizer, REUTERS, European Medicines Agency, Union, BioNTech, European Commission, EMA, U.S, Moderna Inc, EU, United, Medicines, Healthcare, Agency Locations: FRANKFURT, Europe, United States, EU, COVID
COVID will help Asia advance economically on Europe, says Merkel
  + stars: | 2020-12-01 | by ( Reuters Staff | ) www.reuters.com sentiment -0.98   time to read: +2 min
A member of the medical staff in a protective suit treats a patient suffering from the coronavirus disease (COVID-19) in the Intensive Care Unit (ICU) at Havelhoehe community hospital in Berlin, Germany, October 30, 2020. Last month, German police fired water cannon and pepper spray in an effort to scatter thousands of protesters in Berlin angry at coronavirus restrictions. Germany was widely praised for its response to the first coronavirus wave in spring, but it imposed lighter lockdown measures than neighbouring countries as a second wave hit Europe in November and infection numbers have stayed stubbornly high. Schools remain open but private gatherings were limited to five people from Tuesday and fewer people are allowed in shops. “I assume that we will start being able to vaccinate in January at the latest,” German Health Minister Jens Spahn said on an online forum.
Persons: Angela Merkel, Fabrizio Bensch, ” Merkel, , Jan, Jens Spahn Organizations: BERLIN, Intensive Care Unit, REUTERS, lockdowns, Schools, European Medicines Agency, Pfizer, BioNTech, Moderna Locations: Germany, Havelhoehe, Berlin, China, South Korea, Bavarian, Nuremberg
The European Medicines Agency said its officials will work through Christmas to review whether data from trials show sufficient proof of the two vaccines’ safety and effectiveness. If so, the vaccines could be marketed as soon as this month, according to people familiar with the discussions. The EMA is set to make a judgment on the BioNTech vaccine first, by Dec. 29 at the latest, giving that candidate a two-week edge in the vaccine race over Moderna’s candidate. The agency will then decide whether to authorize the Moderna vaccine by Jan. 12, officials said. The submission marked a milestone in the race to supply the world with a working vaccine to end the pandemic, said Ugur Sahin, the chief executive of BioNTech.
Persons: BioNTech, Jan, Ugur Sahin, , ” Dr, Sahin Organizations: BERLIN, Pfizer Inc, drugmaker Moderna Inc, European Union, European Medicines Agency Locations: Italy, Belgium, France
Dollar loses some bounce as focus shifts to Fed
  + stars: | 2020-12-01 | by ( ) www.cnbc.com + 0.00   time to read: +4 min
An under pressure U.S. dollar handed back part of its month-end bounce on Tuesday, as investors reckoned on more monetary easing by the Federal Reserve and a gathering recovery elsewhere. The risk-sensitive Australian and New Zealand dollars edged higher, with the Aussie up 0.3% and the kiwi up 0.5%. The euro rose 0.3%, though all three currencies remained below where they sat before Monday's dollar bounce. Investors are heavily short dollars as optimism about promising vaccine trials drives buying of riskier currencies and higher yielding assets outside the United States. Against a basket of currencies the dollar was a fraction softer at 91.825, after struggling to find traction above 92.000 on Monday.
Persons: Sterling, There's, Jason Wong, Jerome Powell, mull, Powell, Philip Lowe's, Michel Barnier, David Frost, Chris Weston, Bitcoin Organizations: Federal Reserve, New, Fed, Pfizer, Moderna, Reserve Bank of Australia, European Union, EU Locations: United States, Asia, Britain, London, Melbourne
World stocks outperform the U.S. in bumper November
  + stars: | 2020-12-01 | by ( Elliot Smith | ) www.cnbc.com sentiment -0.74   time to read: +2 min
The MSCI World index, which includes 1,603 companies across 23 developed markets, didn't beat it's all-time monthly record, but did close up 12.66% for the month. The pan-European Stoxx 600 index, meanwhile, clocked up its best-ever month in November, ending 13.73% higher. Elsewhere across the world, the MSCI Asia ex-Japan index gained 8% in November and the MSCI Emerging Markets Index was up 9.2%. The month's rally has also been characterized by an apparent rotation towards cyclical stocks, whose performance tends to align with the trajectory of the global economy. Investors have also opted for value stocks — those deemed underpriced relative to their fundamentals — over growth stocks like the big tech names which had driven much of the market recovery from March's crash.
Persons: it's, Joe Biden Organizations: New York Stock Exchange, Dow Jones Industrial, Nasdaq, Pfizer, BioNTech, Moderna, AstraZeneca, U.S, Investors Locations: U.S, Asia, Japan
ET Covid-19 Live Updates: School Policies Shift to Bring Back Younger Children In the U.S., more districts have begun to prioritize elementary students for in-person learning, a policy already in place in much of Europe. There is no plan yet to bring middle and high school students back into city school buildings. Italy has kept its primary schools open but kept teaching remote for middle and high schools. All schools in Germany are open, and discussions about possible closures have focused mainly on high schools. There is wide agreement that frontline health care workers should be prioritized, and the C.D.C.
Persons: Mayor de, Juan Arredondo, Bill de Blasio, , , Elliot Haspel, Gina Raimondo, Michael Osterholm, Joseph R, Biden, , ” — Eliza Shapiro, Atlas, Trump’s, Dr, Scott Atlas, Anna Moneymaker, Scott W, Trump, Atlas’s, Anthony S, Deborah L, Fauci, Stephen Speranza, Alex M, Azar II, Marcus Plescia, Moncef Slaoui, Andy Beshearsaid, Beshear, — Bryan Pietsch, Will Wright, Salgu Organizations: Mayor, The New York Times, Washington D.C, Infectious Disease, University of Minnesota, White, ., The New York, Stanford University, Fox News Channel, White House, Fox News, Twitter, Fox, Centers for Disease Control, NBC, Association of State, Territorial Health Officials, Trump, Politico, Moderna, Pfizer, Food and Drug Administration, Gov, Credit, Alameda County Superior Court, Locations: U.S, Europe, P.S, Brooklyn, New York City, New York, America, Chicago, Washington, Philadelphia, Rhode Island, Italy, Germany, Covid, Cheyenne , Wyoming, States, Kentucky, California, Alameda County, Oakland, Los Angeles
Pfizer, BioNTech apply for coronavirus vaccine approval in Europe
  + stars: | 2020-12-01 | by ( Holly Ellyatt | ) www.cnbc.com + 0.00   time to read: +2 min
U.S. pharmaceutical giant Pfizer and its German partner BioNTech said they have applied to the European Medicines Agency for the conditional marketing authorization of their coronavirus vaccine. If the authorization is granted, it could potentially enable use of Pfizer and BioNTech's vaccine in Europe before the end of 2020, BioNTech said in a press release. "We have known since the beginning of this journey that patients are waiting, and we stand ready to ship Covid-19 vaccine doses as soon as potential authorizations will allow us." The news comes almost two weeks after Pfizer and BioNTech said that final data analysis from the late-stage clinical trial of their coronavirus vaccine showed it was 95% effective in preventing Covid-19 infection. Rival drugmaker Moderna said Monday it will request emergency clearance from the FDA for its coronavirus vaccine after new data confirmed the vaccine was more than 94% effective in preventing Covid-19 and was safe.
Persons: BioNTech, Dr, Albert Bourla, drugmaker Moderna, CNBC's Berkeley Lovelace Organizations: Research Centers of America, Pfizer, European Medicines Agency, CMA, U.S . Food, Drug Administration, FDA, drugmaker Locations: Hollywood , Florida, U.S, Europe, Covid
Pfizer and partner BioNTech said Tuesday they have asked the EU to approve their coronavirus vaccine. Regulator the European Medicines Agency said in a press release that it might not decide whether the COVID-19 vaccine is safe and effective enough until December 29. Approval on December 29 would make an EU vaccine rollout this year almost impossible. The drugmaker's application to the EMA follows authorization applications in the US on November 20 and the UK on November 23. Pfizer and its German partner BioNTech said Tuesday they have asked the European Union to approve their COVID-19 vaccine, but that distribution is unlikely to start until January.
Persons: BioNTech, Pfizer didn't Organizations: Pfizer, European Medicines Agency, EMA, European Union, Street, CMA, COVID, Moderna Locations: European, EU
Total: 25